Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Superoxide dismutase analogue - LTT Bio-Pharma

Next Previous
Drug Profile

Superoxide dismutase analogue - LTT Bio-Pharma

Alternative Names: Lecithin-modified superoxide dismutase - LTT Bio-Pharma; LT-0011; LT-1001 - LTT Bio-Pharma; LT-1002; PC-SOD; PC-SOD NE; Recombinant midismase - LTT Bio-Pharma

Latest Information Update: 15 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LTT Bio-Pharma
  • Developer Beijing Tide Pharmaceutical; Chong Kun Dang; LTT Bio-Pharma
  • Class Anti-inflammatories; Anti-ischaemics; Oxidoreductases
  • Mechanism of Action Antioxidants; Superoxide dismutase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Myocardial reperfusion injury; Peripheral neuropathies; Reperfusion injury; Stroke; Ulcerative colitis
  • Phase I Adult respiratory distress syndrome; Chronic obstructive pulmonary disease
  • No development reported Acute kidney injury; Interstitial lung diseases

Most Recent Events

  • 10 Jul 2025 Phase I development for Chronic obstructive pulmonary disease (Inhalation) is still ongoing (LTT Bio-Pharma pipeline, July 2025)
  • 10 Jul 2025 Phase II development for Myocardial reperfusion injury in China (IV) is still ongoing (LTT Bio-Pharma pipeline, July 2025)
  • 21 Mar 2025 PMDA approves the phase III trial for Peripheral neuropathies in Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top